Andrew Kay has been appointed president and chief executive officer of Algeta ASA of Norway, effective 19 January 2009. Thomas Ramdahl, who has served as CEO since 2001, will take up the position of executive vice president and chief technology officer.
Mr Kay joins Algeta from Renovo Plc where he was executive director of commercial operations. At Renovo, he played an important role in securing a licensing agreement with Shire Plc in 2007 to develop and commercialise Renovo’s product for reducing scarring after surgery, Juvista.
Prior to joining Renovo, Mr Kay was responsible for global sales and marketing of pharmaceuticals at Novartis.
At Algeta, he will focus on finding commercial development partners for the company’s lead cancer product, Alpharadin (radium 223 chloride), which is in Phase 3 development for patients with skeletal metastases from hormone refractory prostate cancer. He will be based in the UK.
Copyright 2008 Evernow Publishing Ltd